Results 1 to 10 of about 250,617 (262)

CAR T cell therapy [PDF]

Immunological Medicine, 2021
Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj   +5 more sources

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions

Cells, 2023
T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman, Oren Yakovian, Naamit Unger Deshet, Shaked Almog, Galit Horn, Tova Waks, Anat Globerson Levin, Eilon Sherman   +7 more
doaj   +1 more source

Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer

Biomedicines, 2022
High-grade serous ovarian carcinoma (HGSOC) is the most common type of epithelial ovarian cancer. The majority of cases are diagnosed at advanced stages, when intraperitoneal (IP) spread has already occurred.
Naamit Deshet-Unger, Galit Horn, Moran Rawet-Slobodkin, Tova Waks, Ido Laskov, Nadav Michaan, Yael Raz, Vered Bar, Adi Zundelevich, Sara Aharon, Lubov Turovsky, Giuseppe Mallel, Seth Salpeter, Guy Neev, Kenneth Samuel Hollander, Ben-Zion Katz, Dan Grisaru, Anat Globerson Levin   +17 more
doaj   +1 more source

Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems

Frontiers in Medicine, 2023
BackgroundManually keeping up-to-date with regulations such as directives, guidance, laws, and ordinances related to cell and gene therapy is a labor-intensive process. We used machine learning (ML) algorithms to create an augmented intelligent system to
William Schaut, Akash Shrivastav, Srikanth Ramakrishnan, Robert Bowden   +3 more
doaj   +1 more source

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

Frontiers in Immunology, 2023
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory ...
Simone Thomas, Simone Thomas, Hinrich Abken, Hinrich Abken   +3 more
doaj   +1 more source

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Frontiers in Immunology, 2020
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell ...
Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni   +9 more
doaj   +1 more source

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Journal of Experimental & Clinical Cancer Research, 2022
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies.
Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu, Huihong Xu, Chong-xian Pan, Zheng Zhu   +5 more
doaj   +1 more source

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo, Feiyan Mo, Mary Kathryn McKenna   +3 more
doaj   +1 more source